state Washington: recent publications

Survey: Persistent Adderall Shortage Disrupts ADHD Treatment Nationwide

September 16, 2022The Adderall shortage reported earlier this summer spurred by labor constraints at a plant run by drug manufacturer Teva Pharmaceuticals is creating a trickle-down effect that is making generic forms of the ADHD medication difficult to find and fill across the United States. According to the American Society of Health-System Pharmacists (ASHP), three additional drug manufacturers — who together with Teva provide one-half of the U.S. supply of generic Adderall — are now reporting supply shortfalls.

Because Adderall (dextroamphetamine-amphetamine, or amphetamine salts) is a Schedule 2 controlled substance, the federal government limits the amount that any one company is allowed to manufacture. When Teva encountered supply shortages earlier this year, its competitors could only absorb so much demand. The result? Patients are now searching multiple pharmacies and waiting up to a month to receive 10-, 15-, 20-, and 30-mg tablets of generic Adderall in both immediate and extended-release formulations.

Though the U.S. Food & Drug Administration is not reporting a formal drug shortage, ADDitude newsletter subscribers surveyed yesterday say the problem is widespread and persistent. Roughly 80% of survey respondents — from Florida, Washington state, Rhode Island, and many places in between — reported encountering some trouble filling or refilling their own or their child’s ADHD medication prescription within the last few months.

Here is some of what they told us: “I am a part-time pharmacy technician and we were running very low on generic Adderall 10-mg just this past Tuesday. I was not able to completely fill a couple of prescriptions for that dosage. The full-time technician who was working stated that it has

. treating adults treating kids Manufacturing

Related articles